DexCom, Inc. (NASDAQ:DXCM) Shares Acquired by Sanctuary Advisors LLC

Sanctuary Advisors LLC grew its holdings in DexCom, Inc. (NASDAQ:DXCM) by 21.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,061 shares of the medical device company’s stock after purchasing an additional 3,226 shares during the quarter. Sanctuary Advisors LLC’s holdings in DexCom were worth $1,405,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Blue Trust Inc. boosted its position in DexCom by 101.9% during the third quarter. Blue Trust Inc. now owns 1,779 shares of the medical device company’s stock worth $119,000 after acquiring an additional 898 shares during the last quarter. Private Advisor Group LLC raised its stake in shares of DexCom by 5.7% in the 3rd quarter. Private Advisor Group LLC now owns 11,318 shares of the medical device company’s stock valued at $759,000 after acquiring an additional 608 shares during the period. International Assets Investment Management LLC purchased a new position in shares of DexCom in the 3rd quarter valued at $930,000. Hennion & Walsh Asset Management Inc. increased its stake in DexCom by 15.1% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 4,409 shares of the medical device company’s stock worth $296,000 after buying an additional 579 shares during the period. Finally, Forsta AP Fonden increased its stake in DexCom by 16.6% during the 3rd quarter. Forsta AP Fonden now owns 83,700 shares of the medical device company’s stock worth $5,611,000 after buying an additional 11,900 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at DexCom

In related news, CEO Kevin R. Sayer sold 33,359 shares of the company’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the transaction, the chief executive officer now directly owns 319,037 shares in the company, valued at $27,727,505.67. This represents a 9.47 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the transaction, the executive vice president now owns 83,526 shares of the company’s stock, valued at approximately $7,259,244.66. This represents a 2.44 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 38,083 shares of company stock worth $3,309,794. 0.30% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

DXCM has been the subject of several recent analyst reports. Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $86.00 to $104.00 in a report on Thursday, January 16th. Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Wells Fargo & Company boosted their target price on shares of DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Canaccord Genuity Group boosted their target price on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research note on Friday, February 14th. Finally, Redburn Atlantic raised shares of DexCom from a “neutral” rating to a “buy” rating and boosted their target price for the company from $85.00 to $115.00 in a research note on Monday, February 3rd. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $99.06.

DexCom Stock Down 2.7 %

DXCM stock opened at $88.32 on Wednesday. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The company’s 50 day simple moving average is $83.78 and its 200-day simple moving average is $76.25. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The firm has a market capitalization of $34.51 billion, a P/E ratio of 61.76, a P/E/G ratio of 2.30 and a beta of 1.14.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, equities research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.